IRINOTECAN AS A THIRD-LINE TREATMENT OF ADVANCED GASTRIC CANCER AFTER FAILURE OF FLUOROPYRIMIDINE, PLATINUM, AND TAXANES

被引：0
|
作者：
Nishimura, Takashi
Iwasa, Satoru
Shoji, Hirokazu
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
机构：
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-17-5
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer
    Norihito Soga
    Hideaki Kise
    Kiminobu Arima
    Yoshiki Sugimura
    International Journal of Clinical Oncology, 2010, 15 : 376 - 381
  • [42] Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: A case report
    Takahashi, N
    Suzuki, H
    Iwabuchi, S
    Yamazaki, Y
    Yanaga, K
    HEPATO-GASTROENTEROLOGY, 2005, 52 (61) : 326 - 328
  • [43] SURVIVAL BENEFIT ASSOCIATED WITH FLUOROPYRIMIDINES, PLATINUM AGENTS, TAXANES, AND IRINOTECAN DURING ALL LINES OF TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Shitara, K.
    Matsuo, K.
    Takahari, D.
    Yokota, T.
    Ura, T.
    Ito, S.
    Sawaki, A.
    Tajika, M.
    Kawai, H.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 228 - 229
  • [44] Taxanes in the Treatment of Advanced Gastric Cancer
    Kang, Byung Woog
    Kwon, Oh-Kyoung
    Chung, Ho Young
    Yu, Wansik
    Kim, Jong Gwang
    MOLECULES, 2016, 21 (05)
  • [45] Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer
    Hyun Jeong Shim
    Ju Young Yun
    Jun Eul Hwang
    Woo Kyun Bae
    Sang Hee Cho
    Ik Joo Chung
    Gastric Cancer, 2011, 14 : 249 - 256
  • [46] Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer
    Shim, Hyun Jeong
    Yun, Ju Young
    Hwang, Jun Eul
    Bae, Woo Kyun
    Cho, Sang Hee
    Chung, Ik Joo
    GASTRIC CANCER, 2011, 14 (03) : 249 - 256
  • [47] Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: Case report
    Shitara, Kohei
    Munakata, Masaki
    Muto, Osamu
    Sakata, Yuh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (07) : 493 - 496
  • [48] Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer.
    Braghiroli, Maria Ignez
    Batistuzzo Vicentini, Maria Fernanda
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Bonadio, Renata Colombo
    Melro Braghiroli, Oddone Freitas
    Machado Mathias, Maria Cecilia
    Talans, Aley
    Zambrano Mendoza, Maria Elizabeth
    Martins, Juliana Goes
    Sabagga, Jorge
    Motta Venchiarutti Moniz, Camila Venchiarutti
    Hoff, Paulo Marcelo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15551 - E15551
  • [49] Prognostic factor for third-line chemotherapy in patients with advanced gastric cancer.
    Choi, Jonggwon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
    Cui, Qingli
    Mao, Yuefeng
    Wu, Daoyuan
    Hu, Yanhui
    Ma, Dongyang
    Zhang, LiHan
    Liu, Huaimin
    FRONTIERS IN ONCOLOGY, 2022, 12
12345